Here's Why Minerva Neurosciences Collapsed Today
The company's lead drug candidate flopped in a phase 3 trial. Can a longer-term follow-up study resurrect the asset?
Here's Why Arcus Biosciences Stock Gained as Much as 15.9% Today
The development-stage biopharma is bouncing back from a recent stock dip.
Here's Why Agenus Rose as Much as 23.3% Today
The biopharma company provided a clinical update for an important pipeline asset.
Is Green Plains a Buy?
The renewable fuel company's stock crashed when governments restricted movement to fight the coronavirus pandemic. Can it recover just as quickly?
Iovance Biotherapeutics Couples Data Release With Stock Offering
The biotech company is looking to raise up to $575 million ahead of its transition to commercial-stage operations.
Is Axsome Therapeutics a Buy?
The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?
Is Coherus BioSciences a Buy?
The biosimilar leader has found quick success with its first major drug product, but the stock's performance hasn't seemed to reflect that.
Is Arrowhead Pharmaceuticals a Buy?
The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.
Should Codexis Investors Prepare for Slower Growth?
The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.
The Case Against Enphase Energy's $200 Million Share Repurchase Program
Shares are at an all-time high and trading at a historic premium. A stock-buyback program could be a terrible use of cash for the high-growth business.
Here's Why Green Plains Roared Higher Today
An analyst upgraded the stock after seeing signs of a recovery in ethanol markets. Investors might not be as enthusiastic.
The Coronavirus Pandemic Is Accelerating the Energy Transition
Energy-related carbon emissions will fall by a record amount in 2020, but a surprising amount of the gains could prove permanent once the economy rebounds.
The Coronavirus Pandemic Is a Big Headwind for Albemarle
The most significant effects might not be felt until the second half of 2020, but investors might expect them to weigh on the dividend stock for the foreseeable future.
Is Another Accounting Issue Brewing for Amyris?
Investors are less than two years removed from a significant accounting discrepancy. A closer look at SEC filings reveals another potential cause for concern.
Here's Why Silver Stocks Rose Today
A steady stream of souring economic data is driving gold and silver prices higher.
Here's Why Allogene Therapeutics Is Roaring Higher Today
The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.
Is Amyris Finally Turning a Corner?
Investors were pleased by relatively positive operating results in the first quarter of 2020. Can the synthetic biology company turn those results into a durable trend?
Here's Why Mesoblast Is Soaring Today
The business raised new capital to ready for the next phase of expansion.
Invitae Readies Telemedicine Marketing Blitz as Testing Volumes Fall 50%
The company thinks a post-pandemic world will appreciate the need for genetic information more than before, but Invitae must navigate uncertainty in the meantime.
Repligen Bucks Industry Trend, Increases Full-Year 2020 Guidance
The bioprocess equipment leader didn't see a slowdown from the coronavirus pandemic, while expected headwinds in a major business unit failed to materialize.